$50 Million - Follow-OnJoint Bookrunner
$197 Million - Follow-OnJoint Bookrunner
Mersana Therapeutics, Inc.
$98 Million - Follow-OnSole Bookrunner
Biotechnology/MEDACorp Hemophilia Survey Highlights Unmet Need For Next-Gen Disruptor Agents
HCIT / Shift to Value “Stronger than Ever” According to KLAS; MDRX Still Challenged
Healthcare / 2019 Outlook: Macro Visibility Poor, It’s a Stockpicker’s Year in Healthcare